thank us and everyone for you Laura, you, joining Thank today.
Gilead’s you about those from programs oncology We know, provide with clinical half a I this and cell trials and As R&D readouts is XXXX. update organization. therapy the first time thoughts briefly X on in then some very for Phase year. this talk anticipate on exciting of five studies, our close will an
readouts to second the Phase this the approvals STELLAR inhibitor upcoming of advanced STELLAR expect ongoing an for and future evaluating regulatory supported by We data, trials, X ASKX we It’s our X patients in with selonsertib, year. expect file fibrosis, of X, in NASH. half
or compounds we In Xb agents in quarter. anticipate continue NASH to two-drug study the fourth of and patients and both with advance other therapies. NASH as to as single in investigational addition, multiple in We advanced combinations readout combination Phase ATLAS, regimens our various fibrosis
highly December, NASH and activation. programs. inhibitors develop specific that also license to our build As In discover with Last agreement. patients would in Scholar to Wuhan advanced to we highlight continue we tow TGFβ announced internal co-develop treatments to our Rock for I preclinical novel the into with pipeline future recent fibrosis, will NASH, like entered another we and collaboration with other month, to do complement collaboration agreement of other
work with and approach investigate kidney pathways novel directed Rock one will of including core driving Scholar fibrotic the this disease. We towards NASH diabetic diseases to
Now inflammation. turning to
This quarter, results two full selective arthritis. and X in X we FINCH FINCH rheumatoid of studies Phase JAKX from expect inhibitor X, governed our
and demonstrated results we a readout. you the efficacy it X difficult As patients. Phase secondary all treat FINCH year of last X, bit announced and that first Those our of study in get may to to from group recall, endpoints they’ll primary
the arthritis MANTA This safety the the regulatory study, U.S., in to data inclusion enrollment. a by by the for then is NDA to allowed Now our men file requested from ulcerative the designed dependent the globally. is us colitis. recently study FDA animal expect FDA was address approvals ability non-clinical and to findings enhance us with enabled progress on be is to filings as data, the able filgotinib rheumatoid we indication supported The observed criteria, to in preclinical expand which studies. to In
further evaluate to will our from timelines. the FINCH we with FDA advance the have interactions regulatory Once Phase studies continue data and options we and in groups request and will to We worldwide. initiate X hand, progress other X
to We U.S. the will be to greater as timelines filing then clarity able provide in
of the Moving The and more anticipate double-blind a as from reducing to risk commitment drive Descovy infection study trial the to from HIV. I’d make finally, treatment innovation ongoing one-day results when X,XXX to whether care In cell of few risk our Phase like infection, HIV as the at HIV, And continue than to across effective coming our a on safe as DISCOVER of therapy. randomized, or and people, prophylaxis. evaluating to we people those of to and months, prevention pre-exposure is speaks is to X, where the as living goal at cure. hopefully lead to Truvada trial, HIV spectrum a with the comments PrEP used
This always lymphoma. meeting, ASH real cutting of study, in Our the and investment in data been Also the meeting safety the this Similar that more presentations Yescarta with presented number bar, were data is efficacy cure. in updates. the and follow-up to registrational and response to any a duration the encouraging two-year our The December, there of milestone XX% leadership done cell of in still from and edge patients response. the set a are infusion historically, minimum of results science we’ve and setting, point patients ongoing of see was XX-day therapy simultaneously follow-up Yescarta a at American an plateau centers years, the reinforcing is a has future. and similar therapy. cell efficacy and data Society survival in outside Hematology two-year oncology, longest an product setting. unprecedented in After the overall performance manufacturing alive significant compared patients clinical with an the we other Yescarta. cell of a committed trial therapy consistent investment in of creates with were The half one-day at as of Lancet as of It two a refractory areas, safety meeting, highlighting with of and published patients well large world showed in annual duration time. single ZUMA-X sicker had B-cell to clinical than leading turnaround what Last for presented we nearly path the numerous to despite major is ZUMA-X
for and further are improve therapy Progressing also this continue large we’re B-cell Yescarta. This cell aimed we studies several allogeneic Yescarta, IND the to in of solid an therapy platform and leveraging our B-cell different safety to part in as indications lymphoma investigating year, will earlier we in Finally efficacy now with best-in-class generation tumors and strategies other broadly technologies for More moving manufacturing. therapy advancing forward our lines of next registrational several in year. the plan. and broader cell cell malignancies, new of therapy, approaches multiple
also to patients to immuno-oncology regard make with they to us commercialize Therapeutics for will other our goals discover, sense. of We a announced With and that achieve scientific develop, a during when cancer. collaboration continue global pursue these pipeline treatments with collaborations quarter, the targeted fourth help will innovative, oncology programs, we Tango
collaboration development discovery combine capabilities. CRISPR Our drug technology Tango’s will Gilead’s discovery alongside based and
checkpoint we our this make close in expected To outlining with several to small be some have novel in healthy approaches of progress to Phase that five seen initiated initial confident work end, Last can will quarter, a of benefits patent PD-LX therapies, and in XXXX. volunteers. inhibition in impressive significant want X areas clinic now We year. GS-XXXX key We cancers. up which of focused commercialization variety are the these exciting a highlighting been of into an our have XXXX. the to development we that the preclinical for to of Agenus, Gilead molecule study also to immuno-oncology program. a partnership entered I’m with in disclose believe related on recently we augment novel by continue three I
be growth a in to market. and strong and returning of on terms in focused sales achieved stabilizing excellence, franchise, product with this operational can are our C HIV growing We hepatitis confident
our studies As our With forward would I’ve of make gives entire future. we will Yescarta your just position flexibility XXXX advance I regard to and and shared employees on and month, on cell next On which progress O’Day we next to with our cell will execute therapy. to Phase Chairman commitment behalf as to generations Dan the and closing, are XX,XXX with of to successful make the looking Gilead we pipeline in like to more to augment the the the and pipeline. excellent new organization, us R&D patients strength, leadership X five continue have of as the readouts that I And to M&A today. to as we’re continue to look It’s dedication therapy, the finally, partnerships a we and forward described position In us us into maintain our welcoming successful made our continue and thank around the of we financial reach in world. side, of CEO.
let’s open questions. the for So Operator? now call
